AMBLE
Commercial- Indications
- Foot drop, Stroke rehabilitation, Spinal cord injury, Traumatic brain injury
Company intelligence / Profile preview
The company’s flagship product, AMBLE, has been registered with the FDA and launched commercially in select clinics. Clinical results show that AMBLE provides safe and effective assistance for foot drop rehabilitation after stroke and other neurological injuries. The company has received significant NIH funding ($4.5M) to support clinical trials and commercialization efforts.
Key findings include improved mobility, muscle strength, coordination, objective progress tracking via software analytics, and high patient satisfaction.
A soft launch of the commercial product began in select clinics in early/mid–2024.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NextStep Robotics.